上尿路上皮癌术后辅助化疗

摘要/Abstract

摘要：

上尿路上皮癌(UTUC)患者手术后复发率高且预后差。既往临床研究结果多数基于回顾性研究,对于术后辅助化疗是否可以改善患者生存尚有争论。近期临床试验结果支持辅助化疗可改善局部晚期UTUC患者的无瘤生存,含铂类药物方案是术后辅助化疗的标准方案。目前尚缺乏术前新辅助化疗与术后辅助化疗对照的临床研究结果,随着靶向治疗及免疫治疗进展,新药联合辅助治疗方案可能会进一步改善UTUC患者生存。

关键词:泌尿系肿瘤,化学疗法,辅助

Abstract:

Upper tract urothelial carcinoma (UTUC) patients have high recurrent rate and poor survival. Most of the previous studies of adjuvant chemotherapy in UTUC were retrospective and the results were controversial. Recent clinical trials support that adjuvant chemotherapy can improve disease-free survival of patients with locally advanced UTUC and platinum based regimens are standard adjuvant treatment. Currently the clinical trials results about effect comparison between adjuvant treatment and neoadjuvant treatment are limited. With the development of targeted therapy and immunotherapy, combinations with novel agents in the adjuvant setting might further improve the prognosis for locally advanced UTUC.

Key words:Urologic neoplasms,Chemotherapy,adjuvant

王墨培, 马力文. 上尿路上皮癌术后辅助化疗[J]. 国际肿瘤学杂志, 2020, 47(7): 436-439.

Wang Mopei, Ma Liwen. Adjuvant chemotherapy for upper tract urothelial carcinoma[J]. Journal of International Oncology, 2020, 47(7): 436-439.

参考文献24

[1]	Leow JJ, Chong KT, Chang SL, et al. Upper tract urothelial carcinoma: a different disease entity in terms of management[J]. ESMO Open, 2017,1(6):e000126. DOI: 10.1136/esmoopen-2016-000126. doi:10.1136/esmoopen-2016-000126pmid:28848663
[2]	Biswas B, Ganguly S, Ghosh J, et al. Adjuvant chemotherapy for upper tract urothelial carcinoma: is there sufficient evidence?[J]. J Clin Oncol, 2017,35(18):2095-2096. DOI: 10.1200/JCO.2017.72.8600. pmid:28471709
[3]	杜智勇, 秦川, 申忠华, 等. 高风险上尿路尿路上皮癌辅助化疗疗效分析及预后相关因素研究[J]. 中华泌尿外科杂志, 2016,37(11):808-812. DOI: 10.3760/cma.j.issn.1000-6702.2016.11.004.
[4]	Cohen A, Kuchta K, Park S. Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma[J]. Urol Oncol, 2017,35(6):322-327. DOI: 10.1016/j.urolonc.2016.11.018. pmid:28065502
[5]	Quhal F, Mori K, Sari Motlagh R, et al. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis[J]. Int J Clin Oncol, 2020,25(6):1037-1054. DOI: 10.1007/s10147-020-01650-9. doi:10.1007/s10147-020-01650-9pmid:32206939
[6]	Ikeda M, Matsumoto K, Hirayama T, et al. Selected high-risk patients with upper tract urothelial carcinoma treated with radical nephroureterectomy for adjuvant chemotherapy: a multi-institutional retrospective study[J]. Clin Genitourin Cancer, 2018,16(3):e669-e675. DOI: 10.1016/j.clgc.2017.10.014. doi:10.1016/j.clgc.2017.10.014pmid:29239844
[7]	Lee KS, Kim KH, Yoon YE, et al. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy[J]. Korean J Urol, 2015,56(1):41-47. DOI: 10.4111/kju.2015.56.1.41. doi:10.4111/kju.2015.56.1.41pmid:25598935
[8]	罗勇, 冯炳富, 魏德超, 等. 辅助化疗对高危上尿路尿路上皮癌患者生存预后影响的前瞻性对照观察[J]. 中华医学杂志, 2019,99(40):3158-3163. DOI: 10.3760/cma.j.issn.0376-2491.40.007.
[9]	Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer[J]. Cancer, 2015,121(15):2586-2593. DOI: 10.1002/cncr.29387. doi:10.1002/cncr.29387pmid:25872978
[10]	Shirotake S, Kikuchi E, Tanaka N, et al. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience[J]. J Urol, 2015,193(4):1122-1128. DOI: 10.1016/j.juro.2014.10.022. doi:10.1016/j.juro.2014.10.022pmid:25444957
[11]	Leow JJ, Martin-Doyle W, Fay AP, et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma[J]. Eur Urol, 2014,66(3):529-541. DOI: 10.1016/j.eururo.2014.03.003. doi:10.1016/j.eururo.2014.03.003pmid:24680361
[12]	Yafi FA, Tanguay S, Rendon R, et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome[J]. Urol Oncol, 2014, 32(1): 31.e17-31.e3.1E24. DOI: 10.1016/j.urolonc.2012.11.014. doi:10.1016/j.urolonc.2012.11.014
[13]	Singla N, Hutchinson R, Menegaz C, et al. Comparing changes in renal function after radical surgery for upper tract urothelial carcinoma and renal cell carcinoma[J]. Urology, 2016,96:44-53. DOI: 10.1016/j.urology.2016.07.015. doi:10.1016/j.urology.2016.07.015pmid:27443467
[14]	Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2020,395(10232):1268-1277. DOI: 10.1016/S0140-6736(20)30415-3. doi:10.1016/S0140-6736(20)30415-3pmid:32145825
[15]	Gregg RW, Vera-Badillo FE, Booth CM, et al. Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2018,128:58-64. DOI: 10.1016/j.critrevonc.2018.05.005. pmid:29958631
[16]	Seisen T, Krasnow RE, Bellmunt J, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma[J]. J Clin Oncol, 2017,35(8):852-860. DOI: 10.1200/JCO.2016.69.4141. pmid:28045620
[17]	Kim DK, Lee JY, Kim JW, et al. Effect of neoadjuvant chemo-therapy on locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2019,135:59-65. DOI: 10.1016/j.critrevonc.2019.01.019. doi:10.1016/j.critrevonc.2019.01.019pmid:30819447
[18]	Suzman DL, Agrawal S, Ning YM, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy[J]. Oncologist, 2019,24(4):563-569. DOI: 10.1634/theoncologist.2018-0084. pmid:30541754
[19]	Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study[J]. Lancet Oncol, 2017,18(2):212-220. DOI: 10.1016/S1470-2045(17)30007-4. pmid:28081914
[20]	Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase Ⅱ IMvigor210 study[J]. Ann Oncol, 2017,28(12):3044-3050. DOI: 10.1093/annonc/mdx518. pmid:28950298
[21]	Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. Lancet, 2017,389(10064):67-76. DOI: 10.1016/S0140-6736(16)32455-2. doi:10.1016/S0140-6736(16)32455-2pmid:27939400
[22]	Inokuchi J, Yokomizo A, Nishiyama N, et al. Perioperative therapies for urological cancers[J]. Jpn J Clin Oncol, 2020,50(4):357-367. DOI: 10.1093/jjco/hyaa013. doi:10.1093/jjco/hyaa013pmid:32115649
[23]	Moss TJ, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma[J]. Eur Urol, 2017,72(4):641-649. DOI: 10.1016/j.eururo.2017.05.048. doi:10.1016/j.eururo.2017.05.048pmid:28601352
[24]	Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma[J]. N Engl J Med, 2019,381(4):338-348. DOI: 10.1056/NEJMoa1817323. doi:10.1056/NEJMoa1817323pmid:31340094

Adjuvant chemotherapy for upper tract urothelial carcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献24

相关文章15

编辑推荐

Metrics

本文评价

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	萨蔷, 徐航程, 王佳玉.乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[4]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[5]	杨博, 付茂勇.单孔胸腔镜下左上肺舌段癌袖式切除同期行右肺上叶癌切除术1例[J]. 国际肿瘤学杂志, 2024, 51(2): 126-128.
[6]	崔腾璐, 孙鹏飞.鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.
[7]	徐放, 朱文钿.肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[8]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻.胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[9]	巩合义, 伊艳, 张健, 李宝生.局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[10]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟.基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[11]	蔡刚祥, 李境, 许斌.肺癌新辅助免疫治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 366-370.
[12]	杜佳, 李娟, 李钱, 陈姝, 单锦露.新辅助放化疗联合动脉栓塞灌注治疗局部晚期直肠癌1例[J]. 国际肿瘤学杂志, 2022, 49(6): 383-384.
[13]	刘永红, 薛玲博, 白杨, 靳健, 臧春霞, 张博, 李杰.治疗前全身炎症反应指数对乳腺癌新辅助化疗病理完全缓解的预测价值[J]. 国际肿瘤学杂志, 2022, 49(4): 210-215.
[14]	张俊鹏, 于燕燕, 李宝生.lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189.
[15]	刘晓静, 朱明华, 左思, 孟迪, 毕艳, 王伟, 进淑娟.不同治疗方式对三阴性乳腺癌预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 33-38.